–Alfie Brennan, PhD · founder. Medicinal chemist with ten years designing and optimising bifunctional molecules, and a second-time founder. Led the identification of the first degraders of MDM2 and RIPK1; built Evariste's ML-first discovery platform from the ground up and led the team that identified preclinical-candidate PKMYT1 inhibitors.
–Andy Crew, PhD · scientific advisor. First chemistry employee and former CTO of Arvinas, the pioneering degradation company. Assembled and led the team that unlocked oral bioavailability for bifunctionals. Thirty years leading teams in pharma and biotech and supporting successful IPOs and exits.
–Jean-Christophe Harmange, PhD · scientific advisor. SVP of Drug Discovery at Psithera; previously CSO of Triana Biomedicines and Director of Drug Discovery at Constellation Pharmaceuticals. Thirty years leading teams in pharma and biotech, working on epigenetic targets and novel modalities.
–Genghis Lloyd-Harris, MD PhD · advisor. Investment banker and physician scientist with thirty years of transatlantic experience of company building. Investor in residence at Cancer Research Horizons; partner at Abingworth for twenty years and fifteen years at Credit Suisse.